Candel Therapeutics Inc (CADL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Candel Therapeutics Inc (CADL) has a cash flow conversion efficiency ratio of -0.131x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.04 Million) by net assets ($138.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CADL defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Candel Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Candel Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Candel Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Candel Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NORVA24 GROUP AB (PUBL.)
F:WG0
|
N/A |
|
Velesto Energy Bhd
KLSE:5243
|
0.016x |
|
Haier Smart Home Co Ltd
F:690D
|
0.040x |
|
Naphtha
TA:NFTA
|
0.097x |
|
Sunplus Technology Co Ltd
TW:2401
|
0.018x |
|
Hingham Institution for Savings
NASDAQ:HIFS
|
0.023x |
|
Royce Micro Cap Closed Fund
NYSE:RMT
|
-0.003x |
|
EPC Groupe
PA:EXPL
|
0.235x |
Annual Cash Flow Conversion Efficiency for Candel Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Candel Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see CADL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $51.92 Million | $-38.31 Million | -0.738x | -81.10% |
| 2024-12-31 | $66.33 Million | $-27.02 Million | -0.407x | +84.84% |
| 2023-12-31 | $12.74 Million | $-34.24 Million | -2.687x | -308.04% |
| 2022-12-31 | $47.71 Million | $-31.42 Million | -0.658x | -90.09% |
| 2021-12-31 | $64.14 Million | $-22.22 Million | -0.346x | -189.98% |
| 2020-12-31 | $-23.56 Million | $-9.07 Million | 0.385x | -40.23% |
| 2019-12-31 | $-8.04 Million | $-5.18 Million | 0.644x | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more